BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16982759)

  • 1. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
    Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
    Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.
    Ma Q; Guin S; Padhye SS; Zhou YQ; Zhang RW; Wang MH
    Mol Cancer; 2011 May; 10():66. PubMed ID: 21619683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
    Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
    Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration.
    Willett CG; Wang MH; Emanuel RL; Graham SA; Smith DI; Shridhar V; Sugarbaker DJ; Sunday ME
    Am J Respir Cell Mol Biol; 1998 Apr; 18(4):489-96. PubMed ID: 9533936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein.
    Wang MH; Montero-Julian FA; Dauny I; Leonard EJ
    Oncogene; 1996 Nov; 13(10):2167-75. PubMed ID: 8950984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
    Feres KJ; Ischenko I; Hayman MJ
    Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.
    Wang MH; Wang D; Chen YQ
    Carcinogenesis; 2003 Aug; 24(8):1291-300. PubMed ID: 12807733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
    Iwama A; Yamaguchi N; Suda T
    EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor.
    Montero-Julian FA; Dauny I; Flavetta S; Ronsin C; André F; Xerri L; Wang MH; Marvaldi J; Breathnach R; Brailly H
    Hybridoma; 1998 Dec; 17(6):541-51. PubMed ID: 9890710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
    Zou Y; Howell GM; Humphrey LE; Wang J; Brattain MG
    PLoS One; 2013; 8(7):e69992. PubMed ID: 23922886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
    Peace BE; Hughes MJ; Degen SJ; Waltz SE
    Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
    Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
    Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.